Alnylam Reports Completion of Patient Enrollment in P-III HELIOS-B Study for Vutrisiran to Treat ATTR Amyloidosis with Cardiomyopathy

August 10, 2021 Auto Bot Alnylam, ATTR amyloidosis, Clinical Trials, P-III 0

Shots:

  • The company has completed the enrolment in the P-III HELIOS-B study evaluates the efficacy and safety of vutrisiran (25 mg, SC, q3M, for ~ 36 mos.) vs PBO in 600 patients in a ratio (1:1) with ATTR amyloidosis with cardiomyopathy across 123 activated sites in 32 countries
  • The 1EP of the study is to evaluate the efficacy of vutrisiranon on the composite EPs of all-cause mortality and recurrent CV events @30mos. The results are expected in early 2024
  • Vutrisiran is an investigational RNAi therapeutic. Additionally, the company has completed the enrollment of APOLLO-B study in Jun’21 with its expected results in mid-2022

Click here to­ read full press release/ article | Ref: Businesswire | Image: Alnylam

The post Alnylam Reports Completion of Patient Enrollment in P-III HELIOS-B Study for Vutrisiran to Treat ATTR Amyloidosis with Cardiomyopathy first appeared on PharmaShots.